# Pfizer Inc. (PFE)

> Actualizado: 2026-02-03 (Post Q4 2025 Earnings)
> Status: HOLD - FAIRLY VALUED
> Confianza: MEDIA-ALTA (subio post-earnings beat)

## TL;DR

Pfizer es big pharma US #5 por market cap ($145B), atravesando transicion post-COVID con patent cliff 2026-28. **Q4 2025 earnings beat (+16% EPS) confirma guidance FY2026 y dividend intacto.** Re-evaluacion Framework v2.0 muestra fair value ~$27.75, MoS 8.7% - insuficiente para ADD bajo Tier A (15%+), pero HOLD justificado por yield 6.5% y downside protection.

---

## Q4 2025 Earnings Summary (Feb 3, 2026)

| Metric | Consensus | Actual | Result |
|--------|-----------|--------|--------|
| Q4 EPS | $0.57 | **$0.66** | **BEAT +16%** |
| Q4 Revenue | $16.65B | **$17.6B** | **BEAT +6%** |
| FY2026 Guidance | $2.80-3.00 | **$2.80-3.00** | CONFIRMED |
| Dividend | Maintained | **MAINTAINED** | NO CUT |
| Ex-COVID Growth | +5-6% exp | **+9%** | **STRONG** |

**Key Takeaways:**
1. Dividend safe - 17 consecutive years maintained
2. Core business strong - ex-COVID +9% operational growth
3. Metsera $10B obesity acquisition - late but strategic pivot
4. ~20 pivotal pipeline studies starting 2026

**Journal Entry:** thesis/active/PFE/journal/2026-02-03_Q4_earnings.md

---

## Re-Evaluacion Framework v2.0 (2026-02-03)

### Value Trap Checklist

| Factor | Status | Evidencia |
|--------|--------|-----------|
| Industria en declive secular | NO | Pharma defensivo, demografia favorable |
| Disrupcion tecnologica | NO | AI ayuda R&D, no destruye |
| Management destruyendo valor | NO | Track record 2024-25 bueno, beat Q4 |
| Balance deteriorandose | NO | D/E 0.67x estable (pre-Metsera) |
| Insider selling masivo | **NO** | Insiders COMPRANDO (Form 4 2025-26) |
| Dividend cut probable | **NO** | CONFIRMED Q4 2025 - 17 anos maintained |
| Perdida market share >2pp | NO | Portfolio diversificado |
| **ROIC < WACC** | **SI** | ROIC 7% < WACC 8% (transitorio) |
| FCF negativo >2 anos | NO | FCF $12.4B robusto |
| **Goodwill >50% equity** | **SI** | G+I $121.7B / Equity $88.7B = 137% |

**Resultado:** 2/10 factores → NO es value trap, pero senales de alerta (ROIC bajo, riesgo impairment)

---

### Proyeccion Derivada (Projection Framework)

#### TAM Analysis
- Global pharma TAM: ~$1.8T (2025) → $2.3T (2030)
- TAM CAGR: ~6%
- Pfizer market share: ~3.4% (estable post-transition)

#### WACC Derivado
```
Risk-Free Rate (Rf): 4.5% (10Y Treasury)
Beta: 0.65 (pharma defensive)
Equity Risk Premium: 5.5%
Cost of Equity (Ke) = 4.5% + 0.65 x 5.5% = 8.08%

Cost of Debt (Kd): 4.04% pre-tax
Tax Rate: 15%
Kd after-tax: 3.44%

Capital Structure:
  Market Cap: $145B (70.8%)
  Net Debt: $60.2B (29.2%)

WACC = 70.8% x 8.08% + 29.2% x 3.44% = 6.72%
WACC Ajustado (pipeline risk): 8.0%
```

#### Revenue/FCF Projection (Updated Post-Earnings)
- 2026: $59.5-62.5B revenue (guidance confirmed)
- Ex-COVID growth: +9% actual (better than +6% expected)
- FCF: ~$11-12B (estable, cubre dividendo $9.8B)

---

### Valoracion Multi-Metodo (Post-Earnings Update)

#### Metodo 1: DCF (40% peso)
```
Growth: 3.5% (upgraded from 3% due to ex-COVID strength)
WACC: 8% (derivado + risk adjustment)
Terminal: 2.5%
Years: 7

Bear: $17.00 (MoS -33%)
Base: $25.50 (MoS 0%)
Bull: $38.00 (MoS +49%)
```

#### Metodo 2: DDM (60% peso)
```
D0: $1.72/share (confirmed Q4 2025)
Required Return: 8%
Dividend Growth: 2% (base case)

Bear (1% growth): $24.57
Base (2% growth): $29.24
Bull (3% growth): $35.43

Expected Value: $29.62 (MoS +10%)
```

#### Reconciliacion
| Metodo | Fair Value | Peso | Weighted |
|--------|-----------|------|----------|
| DCF Base | $25.50 | 40% | $10.20 |
| DDM Base | $29.24 | 60% | $17.54 |
| **Weighted Average** | | 100% | **$27.74** |

**Precio actual:** $25.53
**Margen de Seguridad:** **+8.7%**

---

### Comparacion: Original vs v2.0 vs Post-Earnings

| Metrica | Original (Jan-27) | v2.0 Pre-Earnings | Post-Earnings |
|---------|------------------|-------------------|---------------|
| Fair Value | $32-35 | $27.52 | **$27.74** |
| Margen Seguridad | 25-36% | 3.2% | **8.7%** |
| Metodo | P/E informal | DCF + DDM | DCF + DDM |
| WACC | "~9%" asumido | 8% calculado | 8% calculado |
| Status | "Barata" | Fair Value | **Fair Value** |
| Confianza | Media | Media | **Media-Alta** |

**Causa cambio post-earnings:** Precio bajo de $26.66 a $25.53 + ligero aumento FV por ex-COVID strength mejora MoS de 3.2% a 8.7%.

---

## El Negocio

### Modelo
Pfizer es **big pharma diversificado**: desarrollo, manufactura y comercializacion de medicamentos + vacunas globalmente.

**Estructura (post-COVID 2026):**
1. **Biopharma** (85-90%): Oncologia (Ibrance), Cardio (Eliquis $6-7B), Immunology, Rare Disease
2. **Vacunas** (10-15%): Prevnar 20 ($5-6B), Comirnaty (declining), RSV
3. **COVID residual**: $1.5B 2026E (vs $56B peak 2022)

### Unit Economics (Pharma-specific)
- R&D Spend: $9-10B/ano (~15% revenue)
- Drug approval success rate: ~10-15% (Phase 1 to approval)
- Average cost per approved drug: ~$1-2B
- Patent life: 10-15 anos post-approval
- Gross margin: 70-75%
- Operating margin: 20-25%

### Por Que Esta "Barata" (Mercado vs Mi Tesis)

**Narrativa del mercado:**
1. Patent cliff 2026-28 ($17-18B revenue loss)
2. Obesity pipeline late (Lilly/Novo dominan)
3. Post-COVID overhang (inversores quemados -50%)
4. ROIC < WACC (valor destruyendose temporalmente)

**Mi contra-tesis:**
1. Patent cliff es CONOCIDO y ya en guidance → partially priced
2. Obesity es OPCION, no requisito para thesis (Metsera $10B adds optionality)
3. Yield 6.5% cushion = downside protected
4. FCF $12B solido, dividendo sostenible (CONFIRMED Q4 2025)

**Probabilidad de que este equivocado:** 30-35% (mejorado de 35-40% post-beat)

---

## Moat

**Rating: WIDE pero EROSIONANDO temporalmente**

- Patents (core): 108 drugs en pipeline, 20 pivotal studies 2026, pero $17-18B LOE 2026-28
- Scale & Manufacturing: Global capacity, mRNA platform
- Brand: Reconocimiento global, pero switching costs bajos

**Durabilidad:** Wide moat historico, en transicion critica. Si pipeline ejecuta → wide restored. Si falla → narrow permanente.

---

## Financials (Q4 2025)

| Metrica | Valor | Comentario |
|---------|-------|------------|
| Market Cap | $145B | #5 big pharma |
| P/E TTM | 14.8x | vs sector 15-18x |
| P/E Forward | ~9x | Si guidance $2.90 cumple |
| Dividend Yield | 6.5% | Highest big pharma |
| Payout Ratio | ~100% | Riesgo si EPS cae |
| Debt/Equity | 0.67x | Solido (pre-Metsera) |
| FCF | $12.4B | Cubre dividendo $9.8B |
| ROIC | 7.0% | < WACC (transitorio) |

---

## Riesgos

1. **Patent Cliff Execution** (30-35% prob): Pipeline NO repone $17-18B → EPS decline → div at risk
2. **Obesity Late-to-Market** (50-60% prob): Metsera late, Lilly/Novo dominan → upside limitado
3. **Dividend Cut** (10-15% prob): Payout 100%, pero FCF cubre - reducido post-confirmation
4. **Goodwill Impairment** (25-30% prob): $121.7B G+I, si drugs fallan → write-down
5. **Metsera Integration Risk** (20-30% prob): $10B acquisition adds execution risk

---

## Decision v2.0 (Updated Post-Earnings)

### Status: HOLD - FAIRLY VALUED

| Accion | Trigger | Justificacion |
|--------|---------|---------------|
| **HOLD** | Actual ($25.53) | MoS 8.7%, yield 6.5% protege |
| **ADD** | <$24.00 | MoS sube a 15%+ (Tier A threshold) |
| **STRONG ADD** | <$22.00 | MoS 21%+, excellent entry |
| **TRIM** | >$30.00 | Approaching bull FV |
| **SELL** | >$32.50 o Div cut | Bull FV reached o thesis broken |

### Kill Conditions (All Clear Post-Earnings)
1. Dividend recortado → SELL INMEDIATO (NOT TRIGGERED)
2. FY2026 guidance <$2.50 EPS → REVIEW urgente (NOT TRIGGERED - $2.80-3.00)
3. FCF <$8B sostenido → SELL (NOT TRIGGERED)
4. Pipeline colapso total → SELL (NOT TRIGGERED - 20 pivotal starts)

### Posicion Actual
- Shares: 18.66
- Avg Cost: $26.75
- Current Price: $25.53
- Value: ~$476
- Weight: ~4.3%
- P&L: -$23 (-4.6%)

---

## Catalysts & Calendar

### Near-Term (0-6 months)
| Event | Timing | Impact |
|-------|--------|--------|
| Q1 2026 Earnings | Apr/May 2026 | Monitor guidance progress |
| Metsera Integration | Q1-Q2 2026 | Watch for execution |
| Dividend Declaration | Q1 2026 | Any increase? |
| Pipeline Phase 3s | Throughout 2026 | De-risking catalyst |

### Long-Term (6-24 months)
- Eliquis biosimilar prep (2028 LOE)
- Obesity drug progress (Metsera portfolio)
- mRNA platform expansion

---

## Autocritica v2.0

**Lo que el analisis original fallo:**
1. Uso P/E comparativo sin derivar WACC → sobreestimo fair value
2. No completo value trap checklist formal
3. Asumio "yield cushion" sin calcular DDM formalmente
4. No reconocio que ROIC < WACC es senal de alerta

**Lo que Q4 2025 valida:**
1. Dividend safety - confirmed, 17 years intact
2. Ex-COVID growth strong (+9%) - core business healthier than expected
3. Management execution - beat expectations
4. Pipeline active - 20 pivotal studies shows investment continuing

**Aprendizaje:**
- El nuevo framework reduce el sesgo del "yield atractivo"
- Derivar WACC desde primeros principios da resultados mas conservadores
- DDM + DCF combinados dan imagen mas completa que P/E solo
- Post-earnings beats justify small confidence bump but NOT material FV change

---

## Fuentes

- [Pfizer Investor Relations](https://investors.pfizer.com/)
- [Pfizer Q4 2025 Earnings Release - Feb 3, 2026]
- [OpenInsider - PFE Form 4](http://openinsider.com/PFE)
- [Grand View Research - Pharma Market](https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report)
- [MarketBeat - PFE Financials](https://www.marketbeat.com/stocks/NYSE/PFE/financials/)
